-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
NCT04446429 is a double-blind and placebo-controlled clinical trial designed to explore the role of anti-androgen drugs in fighting new coronavirus infections.
the clinical trial included non-hospitalized male subjects over the age of 50 with androgenic hair loss, all of who had mild or moderate COVID-19.
the study used evythromycin and azithromycin as a standard treatment.
trials were set up in three groups, including the trial group that received "dotamphetamine plus standard treatment", the trial group that received "pruamine plus standard treatment" and the control group that received "placebo plus standard treatment".
the end of the clinical trial included the percentage of subjects hospitalized for COVID-19, the time of remission, and the severity of symptoms, including 26 clinical symptoms, from mild fever to loss of smell.
note: There are deletions in the original text